$Verastem (VSTM.US)$
Revolutionary KRAS G12D Cancer Drug Gets FDA Green Light Following Promising Patient Responses

$Verastem (VSTM.US)$ Reuters· 15 mins ago
Verastem Oncology Announces U.S. Ind Clearance of Vs-7375, Oral Kras G12D (on/off) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

$Verastem (VSTM.US)$
Verastem Oncology's Strategic Move: 247K Share Package Ties New Talent to Sales Goals

$Verastem (VSTM.US)$
Revolutionary Cancer Drug Achieves Complete Response in Colorectal Cancer Study

$Verastem (VSTM.US)$
FDA Fast-Tracks Verastem's Cancer Drug as Company Reports $151M Cash Position

$Verastem (VSTM.US)$
Can This New Ovarian Cancer Drug Transform Treatment? Key Data Reveals Breakthrough Potential

$Verastem (VSTM.US)$ Still holding on. Waiting  for PDUFA action date set for June 30.

$Verastem (VSTM.US)$
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
Thursday, 23rd January at 7:30 am
Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025
Potential U.S. commercial launch in recurrent KRAS mutant LGSOC planned for mid-2025
RAMP 205 trial in 1L metastatic pancreatic cancer cont...

$Verastem (VSTM.US)$ 👀